Pathalys Pharma, Inc.

Pathalys Pharma, Inc. is nearing the clinical trial finish line with upacicalcet, which it is testing in two Phase III trials for the treatment of secondary hyperparathyroidism (SHPT) in patients wit

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sol-Gel Hopes To Bring PellePharm’s Pat

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr